Monopar Therapeutics
MNPR
16 hedge funds and large institutions have $268K invested in Monopar Therapeutics in 2024 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 3 closing their positions.
289% more capital inflows, than outflows
Capital inflows: $125K | Capital outflows: $32.2K
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
14% more funds holding
Funds holding: 14 → 16 (+2)
0.83% more ownership
Funds ownership: 1.83% → 2.66% (+0.83%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$97.2K |
| 2 |
HRT Financial
New York
|
+$19.1K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.28K |
| 4 |
Tower Research Capital (TRC)
New York
|
+$2.52K |
| 5 |
NewEdge Advisors
New Orleans,
Louisiana
|
+$1.79K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$16K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$5.56K |
| 3 |
Two Sigma Investments
New York
|
-$4.87K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.74K |
| 5 |
Virtu Financial
New York
|
-$1.99K |
MNPR Hedge Fund Activity: Q1 2024 in Review
16 of the 6,967 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q1 2024, worth a combined $268K — up 192% from $91.7K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new MNPR positions and 3 closed out — a net gain of 2 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Millennium Management, adding an estimated $97.2K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $16K sold.
- 16 institutional investors held Monopar Therapeutics (MNPR) as of Q1 2024, up from 14 in Q4 2023.
- Funds reported $268K of Monopar Therapeutics stock for Q1 2024, up 192% quarter-over-quarter.
- 5 funds opened new Monopar Therapeutics positions in Q1 2024 and 3 closed out, a net change of +2 holders.
- The largest Monopar Therapeutics buyer in Q1 2024 was Millennium Management, an estimated $97.2K added.
- The largest Monopar Therapeutics seller in Q1 2024 was Renaissance Technologies, an estimated $16K sold.
Based on aggregated 13F filings for Q1 2024.